Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07533032 · ClinicalTrials.gov registry record · NA
Dose-Response Effect of Phosphatidylserine on eSport Performance
A NA study, sponsored by Lindenwood University.
- Completed
- Registry status
- NA
- Development phase
- 80
- Enrollment target
NCT07533032: Completed NA study, sponsored by Lindenwood University.
NCT07533032 is a NA study that has completed, run by Lindenwood University. The registered enrollment target is 80 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07533032, a NA study, has completed, sponsored by Lindenwood University.
- COMPLETED
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
Study Summary
This study will evaluate the effects of daily phosphatidylserine supplementation on electronic gaming performance, cognitive function, sleep quality, stress-related outcomes, and autonomic responses in healthy adult gamers. Participants will be enrolled in a randomized, double-blind, placebo-controlled, parallel-group study and assigned to receive placebo, 100 mg phosphatidylserine, or 200 mg phosphatidylserine daily for 6 weeks. Outcome measures will be assessed at baseline, Week 3, and Week 6 and will include electronic gaming performance, cognitive function, visual analog scale ratings, sleep quality questionnaires, hemodynamic responses, and heart rate variability. The study is designed to determine whether daily phosphatidylserine supplementation can improve performance and selected physiological and psychological outcomes during prolonged electronic gaming sessions.
Primary Outcome
Electronic gaming performance will be assessed using standardized gameplay metrics collected during 60- and 120-minute gaming sessions. Primary variables include knock-outs, falls, damage given, damage taken, hit percentage, and peak damage.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Phosphatidylserine (100 mg)
- DIETARY_SUPPLEMENT Phosphatidylserine (200 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-06-15 |
| Est. Completion | 2025-04-14 |
| Phase | NA |
What the finished NCT07533032 record still lists
NCT07533032 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07533032 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07533032 about?
NCT07533032 is a clinical study titled "Dose-Response Effect of Phosphatidylserine on eSport Performance". This study will evaluate the effects of daily phosphatidylserine supplementation on electronic gaming performance, cognitive function, sleep quality, stress-related outcomes, and autonomic responses in healthy adult gamers. Participants will be enrolled in a randomized, double-blind, placebo-control...
What is the current status of trial NCT07533032?
This trial is currently completed. It is a NA study. The enrollment target is 80 participants. The study started on 2021-06-15. Estimated completion is 2025-04-14.
What interventions are being tested in trial NCT07533032?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Phosphatidylserine (100 mg) (DIETARY_SUPPLEMENT), Phosphatidylserine (200 mg) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07533032?
This trial is sponsored by Lindenwood University, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07533032's enrollment target sits among peer trials
80 994th of 2000 higher than 941 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI